新型冠状病毒感染治疗药物氢溴酸氘瑞米德韦片的临床研发实践

Clinical Research and Development of Deuremidevir Hydrobromide Tablets forthe Treatment of COVID-19

氢溴酸氘瑞米德韦以核苷三磷酸活性形式作用于新型冠状病毒的RNA依赖性RNA聚合酶(Rd Rp),通过结合Rd Rp催化亚基活性中心阻断病毒RNA复制,从而发挥抗病毒作用。2023年1月28日,经国家药品监督管理局应急审评审批,氢溴酸氘瑞米德韦片附条件获批上市,用于治疗轻中度新型冠状病毒感染的成年患者。介绍了氢溴酸氘瑞米德韦片的临床研发实践,旨在为突发公共卫生事件急需药物的研发提供思路与参考。

Deuremidevir hydrobromide acts on the RNA-dependent RNA polymerase(RdRp)of SARS-CoV-2 in the active form of nucleoside triphosphate and blocks viral RNA replication by binding to the active center of the RdRp catalytic subunit,thus playing an antiviral role.On January 28,2023,after the emergency review and approval of the National Medical Products Administration(NMPA),the deuremidevir hydrobromide tablets were conditionally approved for the market,for the treatment of mild to moderate COVID-19 in adult patients.This article introduces the clinical research and development practice of deuremidevir hydrobromide tablets,aiming to provide ideas and reference for the research and development of urgently needed drugs in public health emergencies.